RASH DUE TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS

Clinical trials for RASH DUE TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS explained in plain language.

Never miss a new study

Get alerted when new RASH DUE TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS trials appear

Sign up with your email to follow new studies for RASH DUE TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1

New approach aims to make tough lung cancer treatment more tolerable

Disease control Not yet recruiting

This study is testing whether a comprehensive prevention plan can help Chinese patients with advanced lung cancer better tolerate treatment with the drug amivantamab. The plan aims to reduce common side effects like skin rash, infusion reactions, and blood clots. Researchers will…

Matched conditions: RASH DUE TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS

Phase: PHASE4 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control

Last updated Mar 30, 2026 14:28 UTC

RASH DUE TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS

Get alerted when new RASH DUE TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS trials appear

New approach aims to make tough lung cancer treatment more tolerable